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Dean T. Jamison, Prabhat Jha and David E. Bloom 
 
  This paper identifies priorities for disease control as an input into the Copenhagen 
Consensus effort for 2008 (CC08).  As such, it updates the evidence and differs somewhat in its 
conclusions from the communicable disease paper (Mills and Shilcutt, 2004) prepared for 
Copenhagen Consensus 2004, which Lomborg (2006) summarizes. 
  Our analysis builds on the results of the Disease Control Priorities Project (DCPP).
5 
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The DCPP engaged over 350 authors and among its outputs were estimates of the cost-
effectiveness of 315 interventions.  These estimates vary a good deal in their thoroughness and in 
the extent to which they provide region-specific estimates of both cost and effectiveness.  Taken 
as a whole, however, they represent a comprehensive canvas of disease control opportunities.  
Some interventions are clearly low priority.  Others are attractive and worth doing but either 
address only a relatively small proportion of disease burden or are simply not quite as attractive 
as a few key interventions.  This paper identifies seven priority interventions in terms of their 
cost-effectiveness, the size of the disease burden they address, and other criteria.  Separate but 
related papers for CC08 deal with malnutrition (Behrman, Alderman and Hoddinott, 2007), with 
water and sanitation (Hutton, 2007), with air pollution (Hutton, 2007) and with education 
(Orazem, 2007). It is worth listing our seven priorities at the outset: 
•  Tuberculosis treatment; 
•  Heart attack treatment with generic drugs; 
•  Malaria treatment and prevention package; 
                                                 
5 The DCPP was a joint effort, extending over four years, of the Fogarty International Center of the             
U.S. National Institutes of Health, the World Bank, and the World Health Organization with financial 
support from the Bill & Melinda Gates Foundation.  While the views and conclusions expressed in this 
paper draw principally on the DCPP, others might draw different broad conclusions.  In particular, views 
expressed in this paper are not necessarily those of any of the sponsoring organizations. 
6  The DCPP resulted in two main volumes, both of which Oxford University Press published in 2006.  
One book deals with the Global Burden of Disease and Risk Factors (Lopez et al., 2006).  The other 
book, Disease Control Priorities in Developing Countries, 2
nd edition (Jamison et al., 2006) discusses 
interventions to address diseases and risk factors and the health systems to deliver those interventions.  A 
first edition was published by Oxford University Press for the World Bank in 1993.  This paper will refer 
to these two volumes as DCP1 and DCP2. 
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•  Increased coverage of childhood immunizations; 
•  Tobacco taxation and regulation; 
•  HIV transmission interruption by a “combination prevention” package; and 
•  Improved surgical capacity at district hospitals to treat trauma and ensure safe childbirth. 
 
  Before turning to the substance of the paper it is worth briefly stating our perspectives on 
the roles of the state and of international development assistance in financing health 
interventions. There are major externalities associated with control of many infections and there 
are important public goods aspects to health education and R&D.  One view of the rationale for 
state finance is to address these market failures and to address needs of vulnerable groups.  Our 
view is rather different.  
  Among the OECD countries only the U.S. focuses public finance on vulnerable groups— 
the poor and the elderly. Other OECD countries finance universal coverage for the (generally 
comprehensive) set of health interventions that they finance. Private finance is explicitly 
crowded out by public action, even for purely private clinical services, e.g. fixing broken legs, 
for which most individuals would be willing and able to pay for themselves (perhaps with 
privately financed insurance). Arrow’s (1963) classic paper points to problems of asymmetric 
information and imperfect agency in clinical care and private insurance to which universal public 
finance in one policy response.  At an empirical level the poor outcomes of the U.S. system with 
respect both to health indicators and to total costs (and even with respect to public sector 
expenditures as a percent of GDP) are also suggestive of the merits of universal public finance. 
[See Barr (2001) and Lindert (2004) for more extended discussions.] The perspective of this 
paper is, then one of universal public finance as adopted by the non-U.S. OECD countries.  From 
this perspective one is seeking to maximize health gains or a broader objective function subject 
to a public sector budget constraint without regard for the presence of externalities (except 
insofar as they affect aggregate health) and to address the needs of the poor through selecting 
interventions for universal finance that are of particular importance to the poor. No costs then 
accrue to targeting and no disincentives to work effort result from the potential loss of income-
related health benefits. We further view the political economy of universalism as enhancing 
sustainability. Our perspective on public finance in health leads to less relative emphasis on  
6 
infectious disease control in our short list of high priorities (although four of our seven priorities 
do deal with infection). 
  Our view of the role of international development assistance in health does, in contrast, 
centrally involve externalities and international public goods. Cross-border transmission of 
infection or drug resistance involves important negative externalities.  R&D constitutes a public 
good that has been enormously important in health. Likewise, facilitating diffusion of best 
practice through development assistance or price incentives can be viewed as correction of 
temporary price distortions and hence a reasonable purpose of aid. (Foreign direct investment in 
the private sector is often viewed as an important vehicle for transferring technology and, hence, 
explicit incentives for appropriate technology transfer in health serve a similar purpose.) When 
we discuss the “best buys” in health we do so principally from the perspective of national 
authorities.  But, for investments that may be of importance to development assistance beyond 
their importance from a national perspective, for example for R&D, we point to the role of 
development assistance. 
  Section 1 of the paper documents the enormous success in much of the world in the past 
45 years in improving health in low- and middle-income countries.  Its conclusion is that future 
investments can build on past successes—increasing confidence in the practical feasibility of 
major additional gains in disease control.  Section 2 summarizes evidence that health gains have 
had major economic impact, and Section 3 uses this economic context to describe the methods 
used for the cost-benefit analyses reported.  Sections 4, 5 and 6 discuss problems and 
opportunities in child health, HIV/AIDS and noncommunicable disease.  Section 7 concludes by 
identifying the few most attractive options and presenting (very approximate) cost-benefit 
analyses for them.  This paper emphasizes, although not exclusively, opportunities relevant to 




1.  PROGRESS AND CHALLENGES 
 
Health conditions improved markedly throughout the world during most of the second 
half of the 20
th century; this section begins by highlighting those achievements.  Nonetheless,  
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major problems remained at the beginning of the 21
st century.  Parts of the world have simply not 
kept up with the remarkable progress in other parts; declines in mortality and fertility have led to 
an increasing importance of noncommunicable disease; and the altogether new problem of 
HIV/AIDS has rapidly become prominent in many countries.  Addressing these multiple 
problems within highly constrained budgets will require hard choices, even in the current era of 
expanding domestic health spending and overseas development assistance on health.  This 
section concludes by reviewing these challenges. 
 
1.1  Progress 
 
  Table 1 shows progress in life expectancy by World Bank region between 1960 and 
2005.  For the first three decades of this period, progress was remarkably fast—a gain of          
6.3 years in life expectancy per decade on average, in the low- and middle-income countries, 
albeit with substantial regional variation. Progress continued between 1990 and 2005 but at a 
slower pace. Sub-Saharan Africa actually lost two years of life expectancy   Eastern Europe and 
Central Asia realized no gains. 
In addition to overall progress, since 1950 life expectancy in the median country has 
steadily converged toward the (steadily growing) maximum and hence cross-country differences 
have decreased markedly (Oeppen and Vaupel, 2002).  This reduction in inequality in health 
contrasts with long-term increases in income inequality between and within countries.  Yet 
despite the magnitude of global improvements in health, many countries and populations have 
failed to share in the overall gains or have even fallen behind. Some countries—for example, 
Sierra Leone—remain far behind.  China’s interior provinces lag behind the more advantaged 
coastal regions.  A girl born in rural Madhya Pradesh state (in northern India) has 6 times the risk 
of dying before age 1 as that of a girl born in rural Kerala (in Southern India).  Indigenous people 
everywhere probably lead far less healthy lives than do others in their respective countries, 
although confirmatory data are scant. 
Much of the variation in country outcomes appears to result from the very substantial 
cross-country variation in the rate of diffusion of appropriate health technologies (or ‘technical 
progress’).  Countries range from having essentially no decline in their infant mortality rates 
caused by technical progress to reductions of up to 5 percent per year (Jamison, Sandbu and   
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Table 1     Levels and Changes in Life Expectancy, 1960-2005, 
by World Bank Region 
   Life expectancy (years)     Rate of change (years per decade) 
Region  1960  1990  2005     1960-90  1990-2005 
Low-and middle-income countries 
               
44  
              
63  
              
65    
                      
6.3  
                             
1.7  
  East Asia and the Pacific 
               
39  
              
67  
              
71    
                      
9.3  
                             
2.7  
    (China)               36               69 
              
72     11                             2.0 
  Europe and Central Asia  --  
              
69  
              
69     --  
                                
0.0 
 
Latin America and the     
Caribbean 
               
56  
              
68  
              
72    
                      
4.0  
                             
2.7  
  Middle East and North Africa 
               
47  
              
64  
              
70    
                      
5.7  
                             
4.0  
  South Asia 
               
44  
              
59  
              
63    
                      
4.7  
                
2.7  
 
    (India)               44               59              64    5                             3.3 
  Sub-Saharan Africa 
               
40  
              
49  
              
47    
                      
3.3                            -1.3 
High-income countries 
               
69  
              
76  
              
79    
                      
2.3  
                             
2.0  
World 
               
50  
              
65  
              
68    
                      
5.0  
                             
2.0  
 
Source:  World Bank: World Development Indicators, 2007. 
-- = not available  
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Wang, 2004). Measham et al. (2003) reached a similar conclusion concerning variation in IMR 
decline across the states of India. Cutler, Deaton and Lleras-Muney (2006) provide a 
complementary and extended discussion of the importance of technological diffusion for 
improvements in health.  Consider for example the 10 million child deaths that occur currently 
each year. If child death rates were that seen in OECD countries, fewer than 1 million child 
deaths would occur each year.  Conversely, if child death rates were those in OECD countries 
just 100 years ago, there would be 30 million child deaths a year. The key difference between 
now and then is not income but technical knowledge—about disease causation, interventions, 
and their application. Bloom and Canning (2007) show that population health has tended to show 
continuous advancement among both high- and low-mortality countries over the past four to five 
decades, with some countries accelerating their progress and making a transition from the high-
mortality cluster to the low-mortality cluster. 
Consider the remarkable declines in infectious disease, except for HIV worldwide and 
perhaps malaria in Africa (Table 2).  The development of vaccination, antimicrobial 
chemotherapy, and the ability to characterize new microbes have played key roles in the 
reduction of more than 90% in communicable disease mortality in Canada and the US (US 
Centers for Disease Control and Prevention, 1996).  Today more than 30 common infectious 
diseases are controllable with live or killed viral or bacterial vaccines, or those based on bacterial 
sugars and proteins. In 1970, perhaps only 5% of the world’s children under 5 were immunized 
against measles, tetanus, pertussis, diptheria and polio.  The Expanded Programme on 
Immunization raised this to about 75% of children by 1990, saving perhaps 3 million lives a year 
(England et al, 2001).  The clearest success in immunization is the World Health Organization 
(WHO)-led campaign against smallpox, which culminated in the eradication of smallpox in 
human populations by 1979.  More recently, WHO is engaged in an ongoing effort to eradicate 
poliomyelitis, which is more difficult technically than smallpox eradication. The effort has, 
nonetheless, reduced polio cases to zero in the large majority of countries and to a modest 
number in the rest.  Prior to 1950, the only major antibiotics were sulfonamides and penicillin.  
Subsequently, there has been remarkable growth in discovery and use of antimicrobial agents 
effective against bacteria, fungi, viruses, protozoa and helminths.  Delivery of a combination of 
anti-tuberculosis drugs with direct observation (or DOTS, described below) has lowered case-
fatality rates from well over 60% to 5%, and has also decreased transmission.  The percentage of  
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the world’s tuberculosis cases treated with DOTS has risen from 11% to about 53% (Dye et al, 
2006), which points to the practical possibility of still further gains. 
Research into HIV/AIDS and related diseases is providing a better understanding of the 
internal structure of retroviruses and is accelerating the number of antiviral agents.  Similarly, 
there is increasing knowledge of the modes of action of antifungal and antiparasitic agents 
(Weatherall et al, 2006).  Large-scale studies have been able to identify smoking as a major 
cause of tuberculosis mortality worldwide (Bates et al, 2007) but especially in India (Jha et al, 
2008).  Finally, large-scale randomized trials have been increasingly used to establish widely 
practicable therapies, especially when modest, but important treatment benefits are sought (Peto 
and Baigent, 2003).  Advances in computing and statistics have led to more robust mathematical 
models of infectious disease spread (Nagelkerke et al, 2001). Finally, a new chapter is the 
development of molecular biology and recombinant DNA technology in the second half of the 
20
th century.  The benefits of DNA science to global health are as yet limited but could be 
extraordinary (see Weatherall et al, 2006). These technical advances enable major health 
improvements at low cost. 
Factors from outside the health sector also affect the pace of health improvement:  
education levels of populations appear quite important although the level and growth rate of 
income appear much less so (Jamison, Sandbu and Wang, 2004; Bloom and Canning 2007; 
Bloom 2007).  Hence, the importance of technical progress and diffusion should be viewed in a 
larger context. Expanded education facilitates diffusion of good practices, as in the case of 
maternal education improving child health.  And, although rapid economic growth in many parts 
of the world, especially in coastal China and in urban India, might well mean that some can buy 
their way into better health, this paper argues that there will be far more benefit if expanded 
public coffers are used on a relatively limited set of highly effective public health and clinical 
interventions.  This point bears reiterating in a slightly different way: income growth is neither 
necessary nor sufficient for sustained improvements in health.  Today’s tools for improving 
health are so powerful and inexpensive that health conditions can be reasonably good even in 
countries with low incomes.  
Reasons for remaining health inequalities thus lie only partially in poverty or income 
inequality:  the experiences of China, Costa Rica, Cuba, Sri Lanka, and Kerala state in India, 
among others, conclusively show that dramatic improvements in health can occur without   
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Condition and intervention   Annual deaths prior 
to intervention in 
thousands (and ref 
year) 
Annual deaths after 
intervention in 
thousands (and ref 
year) 
Immunization services - against 
polio, diphtheria, pertussis, 
tetanus and measles 
~5,000 (1960)  1,400 (2001) 
Smallpox eradication campaign   ~3,000 (1950)  0 (1979) 
Diarrhea- oral rehydration 
therapy 
~ 4,600 (1980)  1,600 (2001) 
Malaria outside Africa- indoor 
residual spray and acute 
management 
~ 3,500 (1930)  <50 (1990) 
Malaria in Africa- limited use of 
indoor residual spray and acute 
management 
~300 (1930)  1,000 (1990) 
 
 
Source: Jha, Brown et. al. (2004).  
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high or rapidly growing incomes.  The experiences of countries in Europe in the late 19th and 
early 20th centuries similarly show that health conditions can improve without prior or 
concomitant increases in income (Easterlin 1996).  A recent review identified many specific 
examples of low-cost interventions leading to large and carefully documented health 
improvements (Levine and the What Works Working Group, 2007).  The public sector initiated 
and financed virtually all of these interventions.  The goal of this paper is to assist decision 
makers—particularly those in the public sector—to identify the highest priority low-cost 
interventions to rapidly improve population health and welfare where the needs are greatest. 
 
 
1.2  Remaining Challenges 
       
Three central challenges for health policy ensue from the pace and unevenness of the 
progress just summarized and from the evolving nature of microbial threats to human health. 
Unequal Progress.  The initial challenge results from continued high levels of inequality in 
health conditions across and within countries.  Bloom and Canning (2007) have stressed that 
global inequalities are declining if one properly accounts for convergence across countries in 
health conditions, which more than compensates for income divergence. However, in far too 
many countries health conditions remain unacceptably—and unnecessarily—poor.  This fact is a 
source of grief and misery, and it is a brake on economic growth and poverty reduction. From 
1990 to 2001, for example, the under-5 mortality rate remained stagnant or increased in 23 
countries.  In another 53 countries (including China), the rate of decline in under-5 mortality in 
this period was less than half of the 4.3 percent per year required for each country to reach the 
fourth Millennium Development Goal (MDG-4).  Meeting the MDG for under-5 mortality 
reduction by 2015 is not remotely possible for these countries.  [See Lopez, Begg and Bos (2006) 
for country-specific estimates of child and adult mortality rates in 1990 and 2001 that were 
generated in a consistent way over time and across countries.]  Yet the examples of many other 
countries, often quite poor, show that with the right policies dramatic reductions in mortality are 
possible. A major goal of this paper is to identify strategies for implementing interventions that 
are known to be highly cost-effective for dealing with the health problems in children of  
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countries remaining behind—for example, treatment for diarrhea, pneumonia and malaria; 
immunization; and other preventive measures to reduce stillbirths and neonatal deaths. 
About 10.6 million of the 49 million deaths in low- and middle-income countries occur in 
children between birth and age 5. Table 3 summarizes what is known about the causes of deaths 
under the age of 5, and under the age of 28 days, in 2001.  Table 3 also includes an estimate of 
the number of stillbirths. Figure 1 illustrates that about half of all deaths under the age of 5 
(including stillbirths) occur in the first 28 days, indicating the importance of addressing 
conditions important in this period. 
 
Epidemiological Transition.  A second challenge lies in noncommunicable disease and injury.  
The next two decades will see continuation of rising trends resulting from dramatic fertility 
declines (and consequent population aging) in recent decades.  The combination of an aging 
population paired with increases in smoking and other lifestyle changes mean that the major 
noncommunicable diseases—circulatory system diseases, cancers, respiratory disease and major 
psychiatric disorders—are fast replacing (or adding to) the traditional scourges—particularly 
infectious diseases and undernutrition in children.  Additionally, injuries resulting from road 
traffic are replacing more traditional forms of injury.  Responding to this epidemiological 
transition within sharply constrained resources is a key challenge.  Table 4 provides cause-
specific estimates of the number of deaths over age 5 due to major causes in low- and middle-
income countries.  This summary indicates that noncommunicable disease already accounts for 
two thirds of all deaths over age 5 in these countries, although nearly 22% of deaths continue to 
be from infection, undernutrition and maternal conditions, creating a “dual burden” to which 
Julio Frenk and colleagues have pointed (Bobadilla and others 1993). 
 
HIV/AIDS Epidemic.  A third key challenge is the HIV/AIDS epidemic.  Control efforts and 
successes have been very real in high- and middle-income countries but are not yet widespread 
in low-income countries.  As we outline below, the HIV epidemic is best viewed as a set of 
diverse epidemics in regions or sub-regions. Each region’s epidemic demands understanding the 
reasons for HIV growth, appropriate interventions to decrease transmission to uninfected  
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 Table 3     Causes of Under-5 Mortality, Worldwide in 2001,  
Estimates from the GBD (in thousands)  
 
Cause     
   Total 
(stillbirths to 4)  Age 0 to 4 
        Neonatal   
   (age 0-27days)    Stillbirths 
                 
HIV/AIDS              340        340       
Diarrheal Disease       1,600     1,600        116   
Measles              557        557       
Tetanus            187        187        187   
Malaria           1,087     1,087       
Respiratory infection (and sepsis)     1,945     1,945             1,013   
Low birth weight        1,301     1,301             1,098   
Birth asphyxia and birth trauma        739       739       739   
Congenital anomalies        439       439        321      
Injuries            310       310     
Other           5,375     2,101        446          3,274 
             
TOTAL         13,874  10,600      3,900          3,274 
 
Source:  Mathers, Lopez and Murray (2006); Jamison et al. (2006). 
 
Notes:    1.  Of the estimated 13.9 million under-5 deaths in 2001 only 0.9% 
occurred in high-income countries.  Thus the cause distribution of deaths in this  
table is essentially that of low- and middle-income countries. 
2.  ‘Stillbirths’ are defined as fetal loss in the third trimester of pregnancy. 
About 33% of stillbirths occur after labor has begun – so-called intrapartum  
stillbirths.  No good estimates exist for stillbirths by cause, but some of the cause 
categories (e.g., birth asphyxia, birth trauma, congenital anomalies) are the same as 
for age 0 to 4 so part of what is categorized as ‘other’ in the total row will be 









Figure 1   Age Distribution of Deaths of Children 






















Table 4    Causes of Death in Low- and Middle-Income Countries,  




                   Deaths (in millions)          % of total 
 
 
1.  Communicable, maternal, perinatal and 
     nutritional conditions 
TB                1.5 million         4.0% 
AIDS                 2.2           5.8 
Respiratory infections           1.5             4.0 
Maternal conditions              0.5            1.3 
Other                 2.5                     _6.6 
 
Subtotal                 8.2                     21.7 
 
2.   Noncommunicable disease 
Cancers                 4.9        13.0 
Diabetes                 0.7            1.9 
Ischaemic and hypertensive heart disease         6.5          17.2 
Stroke                4.6          12.2 
Chronic obstructive pulmonary disease         2.4            6.3 
Other                 6.1          16.1 
 
Subtotal               25.2          66.7 
 
3.  Injuries 
Road traffic accidents            1.0            2.6 
Suicides               0.7             1.9 
Other                           2.7            7.1 
 
Subtotal               4.4        11.6 
 
TOTAL                  37.8 million                100 % 
 
 
Source:  Aggregated from Mathers, Lopez and Murray (2006, pp. 126-131). 
  
17 
populations, and clinical care with life-prolonging drugs for those already infected.  Recent data 
suggest that outside parts of Eastern and Southern Africa, growth of HIV is slowing (including in 
large parts of Asia, Latin America and elsewhere), and that such reductions might be due to a 
(very uneven) increase in prevention programs. 
 
2.    THE ECONOMIC BENEFITS OF BETTER HEALTH 
 
 The dramatic health improvements globally during the 20
th century arguably contributed 
as much or more to improvements in overall well-being as did the equally dramatic innovation in 
and expansion of the availability of material goods and services.  To the substantial extent that 
appropriate investments in health can contribute to continued reductions in morbidity and 
mortality, the economic welfare returns to health investments are likely to be exceptional and 
positive—with previously unrecognized implications for public sector resource allocation. The 
purpose of this section is to explain the high values this paper places on mortality reduction in its 
cost-benefit analyses.  Returns to better health go far beyond the contribution better health makes 
to per person income, which itself appears substantial (see Bloom, Canning, and Jamison 2004; 
Lopez-Casasnovas, Rivera, and Currais 2005).  This section first summarizes the evidence 
concerning health’s effect on per person income and then turns to more recent literature 
concerning the effect of health changes on a broader measure of economic well-being than per 
person income. 
 
2.1  Health and Income 
 
  How does health influence income per person? One obvious linkage is that healthy 
workers are more productive than workers who are similar but not healthy.  Supporting evidence 
for this plausible observation comes from studies that link investments in health and nutrition of 
the young to adult wages (Strauss and Thomas 1998).  Better health also raises per person 
income through a number of other channels. One involves altering decisions about expenditures 
and savings over the life cycle.  The idea of planning for retirement occurs only when mortality 
rates become low enough for retirement to be a realistic prospect.  Rising longevity in 
developing countries has opened a new incentive for the current generation to invest in physical  
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capital and in education—an incentive that can dramatically affect national saving rates. 
Although a saving boom may be offset by the needs of the elderly after population aging occurs, 
it can substantially boost investment and economic growth rates while it lasts. 
Encouraging foreign direct investment is another channel: investors shun environments in 
which the labor force suffers a heavy disease burden and where they may themselves be at risk 
(Alsan, Bloom, and Canning, 2006).  Endemic diseases can also deny humans access to land or 
other natural resources, as occurred in much of West Africa before the successful control of river 
blindness.  Boosting education is yet another channel. Healthier children attend school and learn 
more while they are there.   
Demographic channels also play an important role.  Lower infant mortality initially 
creates a “baby-boom” cohort and leads to a subsequent reduction in the birth rate as families 
choose to have fewer children in the new low-mortality regime.  A baby-boom cohort affects the 
economy profoundly as its members enter the educational system, find employment, save for 
retirement, leave the labor market, and finally become dependents again.  The cohorts before and 
after a baby boom are much smaller; hence, for a substantial transition period, this cohort creates 
a large labor force relative to overall population size and the potential for accelerated economic 
growth (Bloom and Canning, 2006; Bloom and Canning, 2008). 
If better health improves the productive potential of individuals, good health should 
accompany higher levels of national income in the long run.  However, as Acemoglu and 
Johnson (2007) suggest, effects on per person income may also be adversely affected by health-
related population increases.  How big a net contribution does better health make to economic 
growth? Evidence from cross-country growth regressions suggests the contribution is 
consistently substantial. Indeed, the initial health of a population has been identified as one of the 
most robust drivers of economic growth—among such well-established influences as the initial 
level of income per capita (negatively), geographic location, and institutional and economic 
policy environment. Bloom, Canning, and Sevilla (2004) find that one extra year of life 
expectancy raises GDP per person by about 4 percent in the long run. Jamison, Lau, and Wang 
(2005) estimate that reductions in adult mortality explain 10 to 15 percent of the economic 
growth that occurred from 1960 to 1990.  Although attribution of causality is never unequivocal 
in analyses like these, household-level evidence also points consistently to a likely causal effect 
of health on income.   
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Health declines can precipitate downward spirals, setting off impoverishment and further 
ill health.  For example, the effect of HIV/AIDS on per capita GDP could prove devastating in 
the long run.  The International Monetary Fund published a collection of important studies of the 
multiple mechanisms through which a major AIDS epidemic could be expected to affect national 
economies (Haacker 2004). 
 
2.2  Health and Economic Welfare 
 
Judging countries’ economic performance by GDP per person fails to differentiate 
between situations in which health conditions differ: a country whose citizens enjoy long and 
healthy lives clearly outperforms another with the same GDP per person but whose citizens 
suffer much illness and die sooner.  Schelling (1968) initiated efforts to assign economic value to 
changes in mortality probability and Johannson (1995) provides an up-to-date explication of the 
theory.  Individual willingness to forgo income to work in safer environments and social 
willingness to pay for health-enhancing safety and environmental regulations provide measures, 
albeit approximate, of the value of differences in mortality rates.  Many such willingness-to-pay 
studies have been undertaken in recent decades, and their results are typically summarized as the 
value of a statistical life (VSL).  
Although the national income and product accounts include the value of inputs into 
health care (such as drugs and physician time), standard procedures do not incorporate 
information on the value of changes in longevity.  In a seminal paper, Usher (1973) first brought 
estimates of VSL into national income accounting. He did this by adding estimates of the value 
of changes in annual mortality rates (calculated using VSL figures) to changes in annual GDP 
per person.  These estimates are conservative in that they incorporate only the value of mortality 
changes and do not account for the total value of changes in health status.  This paper will later 
use a measure of ‘disability-adjusted life years’, or DALY, that includes disability as well as 
premature mortality in a way that calibrates disability weight in terms of mortality changes.  
[Valuation of changes in mortality, it should be noted, is only one element—albeit a 
quantitatively important one—of potentially feasible additions to national accounts to deal with 
outcomes for which there are not market prices.  The U.S. National Academy of Sciences has 
recently proposed broad changes for the United States that would include but go beyond  
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valuation of mortality change (Abraham and Mackie 2005).  Of specific relevance to this paper is 
the economic welfare value of reductions in financial risk potentially associated either with a 
health intervention—typically prevention or early treatment—or with a risk-pooled way of 
financing it. Although we don’t try to quantify this effect, we do provide a broad assessment of 
the impact of our priority interventions on financial risk.] 
For many years, little further work was done on the effects of mortality change on full 
income, although, as Viscusi and Aldy (2003) document, the number of carefully constructed 
estimates of VSLs increased enormously.  Bourguignon and Morrisson (2002) address the long-
term evolution of inequality among world citizens, starting from the premise that a 
“…comprehensive definition of economic well-being would consider individuals over their 
lifetime.”  Their conclusion is that rapid increases in life expectancy in poorer countries have 
resulted in declines in inequality (broadly defined) beginning sometime after 1950, even though 
income inequality had continued to rise.  In another important paper, Nordhaus (2003) assesses 
the growth of income plus the growth in the value of mortality change per capita in the United 
States in the 20
th century.  He concludes that more than half of the growth in this indicator in the 
first half of the century—and somewhat less than half in the second half of the century—had 
resulted from mortality decline. In this period, real income in the United States increased six-fold 
and life expectancy increased by more than 25 years.   
Three lines of more recent work extend those methods to the interpretation of the 
economic performance of developing countries.  All reach conclusions that differ substantially 
from analyses based on GDP alone.  Two of those studies—one undertaken for the Commission 
on Macroeconomics and Health (CMH) of the World Health Organization (WHO) (Jamison, 
Sachs, and Wang 2001) and the other at the International Monetary Fund (Crafts and Haacker 
2004)—assessed the impact of the AIDS epidemic.  Both studies conclude that the AIDS 
epidemic in the 1990s had far more adverse economic consequences than previous estimates of 
effects on per person GDP growth would suggest.  The benefit estimates used in this paper for 
successful interventions against HIV/AIDS are consistent with these findings from the CMH and 
IMF.  Accounting for mortality decline in Africa before the 1990s, on the other hand, leads to 
estimates of much more favorable overall economic performance than does the trend in GDP per 
person.  Figure 2 shows that in Kenya, for example, full income grew more rapidly than did GDP 
per person before 1990 (and far more rapidly in the 1960s). After 1990 the mounting death toll  
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from AIDS appears to have only a modest effect on GDP per person but a dramatically adverse 
impact on changes in full income. Becker, Philipson, and Soares (2003) confirm and extend the 
earlier work of Bourguignon and Morrisson (2002) in finding strong absolute convergence in full 
income across countries over time, in contrast to the standard finding of continued divergence 
(increased inequality) of GDP per person.  Finally, Jamison, Jamison, and Sachs (2003) adapt 
standard cross-country growth regressions to model determinants of full income (rather than 
GDP per person).  Like Bourguignon and Morrisson (2002), they conclude that inequalities have 
been decreasing. 
The dramatic mortality declines of the past 150 years—and their reversal in Africa by 
AIDS after 1990—have had major economic consequences. The effect of health on GDP is 
substantial.  The intrinsic value of mortality changes—measured in terms of VSL—is even more 
substantial.  What are the implications of these findings for development strategy and for cost-
benefit analyses of public sector investment options?  Using full income in cost-benefit analyses 
of investments in health (and in health-related sectors such as education, water supply and 
sanitation, and targeted food transfers) would markedly increase estimates of net benefits or rates 
of return.  A major purpose of the Copenhagen Consensus process is to undertake intersectoral 
comparison of investment priorities by utilizing this ‘full benefit’ approach.  
 
3.  COST-BENEFIT METHODOLOGY 
 
The basic approach to cost-benefit analysis used in this paper is to start with the cost-
effectiveness (CE) results from the extensive comparative analyses reported in DCP2 (Jamison et 
al., 2006; Laxminarayan et al. 2006).  These results are expressed as the cost of averting a 
DALY, a summary measure involving mortality change and a valuation of disability change that 
can be considered to have been generated by calibration against mortality change. 
Section 3.1 describes an idealized version of our approach to CE – idealized in the sense 
that it seeks to explicitly call attention to the value of financial protection and nonfinancial costs 
(e.g., use of limited system capacity).  The point is to serve as a reminder in drawing conclusions 
about some specific important considerations that go beyond the CE ratios reported.  Section 3.2 
discusses DALYs and explicitly argues for a change in the way DALYs associated with deaths 
under the age of 5 are calculated.  This change, which is adopted in our cost-benefit (CB)  
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analyses, reduces the averted-DALY cost of a typical death under age 5 by about 50% while 
leaving the construction of DALYs for older ages unchanged.  Section 3.3 draws on Section 2 to 
assign, very conservatively, dollar values to DALYs for the subsequent CB assessment.  Section 
3.4 summarizes this paper’s approach to costing. 
 
3.1  Cost-effectiveness analysis broadly and narrowly construed 
 
A starting point for cost-effectiveness analysis broadly construed is to observe that health 
systems have two main objectives:  (a) to improve the level and distribution of health outcomes 
in the population and (b) to protect individuals from financial risks that are often very substantial 
and that are frequent causes of poverty (WHO 1999, 2000).  Financial risk results from illness-
related loss of income as well as expenditures on care; the loss can be ameliorated by preventing 
illness or its progression and by using appropriate financial architecture for the system. 
We can also consider two classes of resources to be available: financial resources and 
health system capacity.  To implement an intervention in a population, the system uses some of 
each resource.  Just as some interventions have higher dollar costs than others, some 
interventions are more demanding of system capacity than others.  In countries with limited 
health system capacity, it is clearly important to select interventions that require relatively little 
of such capacity.  An implication is that in limited-capacity countries, interventions should 
sometimes be skewed toward the use of financial resources to conserve on system capacity. 
Human resource capacity constitutes a particularly important aspect of system capacity, 
discussed in a recent report of the Joint Learning Initiative (2004).  Figure 3 illustrates this 
broadly construed vision of CE and, in its shaded region, the more narrow (standard) approach 
for which quantitative estimates are available. Jamison (2008) provides a more extended 
discussion. 
Although in the very short run there may be little opportunity to substitute dollars for 
human resources or system capacity more generally, investing in the development of such 
capacity (which will often require foreign aid or investment) can help make more of that 
resource available in the future.  Mills, et al. (2006) discuss different types of health system 
capacity and intervention complexity and point to the potential for responding to low capacity by  
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selecting interventions that are less demanding of capacity and by simplifying interventions.  
Mills, et al. also explore the extent to which financial resources can substitute for different 
aspects of system capacity (see also Gericke, et al. 2003).  An important mechanism for 
strengthening capacity, inherent in highly outcome-oriented programs, may simply be to use it 
successfully—learning by doing. 
The literature on economic evaluation of health projects typically reports the cost per unit 
of achieving some measure of health outcome—quality-adjusted life years (QALYs) or DALYs 
or deaths averted—and at times addresses how that cost varies with the level of intervention and 
other factors.  Pritchard (2004) provides a valuable introduction to this literature.  DCP1 reported 
such cost-effectiveness findings for about 70 interventions; DCP2 does so as well, in the end 
providing evidence on about 315 interventions. DCP2 authors were asked to use methods 
described in Jamison (2003).  Cost-effectiveness calculations provide important insights into the 
economic attractiveness of an intervention, but other considerations—such as consequences for 
financial protection and demands on health system capacity—need to be borne in mind. 
 
3.2  Defining and Redefining DALYs 
     
The DALY family of indicators measures the disease burden from the age of onset of a 
condition by summing an indicator of years of life lost (YLL) due to the condition and an 
indicator of years of effective life lost due to disability (YLD) resulting from the condition.  
Disability-adjusted life years (DALYs) due to a condition are the sum of the relevant YLLs and 
YLDs.   
DALYs generate a measure of the disease burden resulting from premature mortality by 
integrating a discounted, potentially age-weighted, disability-adjusted stream of life years from 
the age of incidence of the condition to infinity using a survival curve based on the otherwise 
expected age of death.  The formulation within the family of DALYs previously used to 
empirically assess the global burden of disease specifies a constant discount rate of 3 percent per 
year and an age-weighting function that gives low weight to a year lived in early childhood and 
older ages and greater weight to middle ages.  The current comprehensive volume on burden of 
disease reports global burden of disease estimates generated with the 3% discount rate but 
uniform age weights (Lopez, et al., 2006a).  Mathers et al. (2006) provide an extensive  
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exploration of the uncertainty and sensitivity inherent in disease burden assessment, including 
the results of differing assumptions about age weighting and discount rates. 
To be clear about the particular form of DALY being used, the terminology from Mathers 
et al. is employed.  DALYs(r,K) are DALYs constructed using a discount rate of r percent per 
year and an amount of age weighting indexed by a parameter K.  DALYs(3,1) are DALYs 
generated with a discount rate of 3 percent per year and with full age weighting, that is, K = 1.  
DALYs(3,0) are DALYs generated with a discount rate of 3 percent per year and with no age 
weighting, that is,  K = 0.  Mathers, Lopez and Murray (2006) present results concerning the 
burden of disease based on DALYs(3,0); Ezzati, et al. (2006) present estimates of the burden of 
major risk factors.  This paper is based on DALYs (3,0), but slightly generalized. 
This paper uses an extension of the DALY family generated by modeling a concept of 
‘acquisition of life potential’, ALP.  The intuition behind the ALP concept is that an infant (or 
fetus) only gradually acquires the full life potential reflected in a stream of life years, that is, 
ALP can be gradual, i.e. there is no single time point during gestation, or at birth, when the fetus 
makes an abrupt transition from zero to full life potential.  Operationalizing this concept involves 
introducing a parameter, A, that indicates the speed of ALP (see Jamison, et al., 2006 for precise 
definitions and assessments of the burden of disease that result.)  A is constructed so that for the 
fastest possible speed of ALP, namely, instantaneous ALP, A = 1. A is bounded below by 0.  
This chapter extends the notation DALYs(r,K) in two ways.  First, it explicitly indicates the level 
of A by extending the DALY nomenclature to DALYs(r,K,A).  Thus using this nomenclature, 
DALYs(3,0) become DALYs(3,0,1), because the standard DALY is the special case with 
instantaneous ALP.  Second, when stillbirths are included in the range of events to be measured 
in the global burden of disease, this is explicitly noted in the DALY nomenclature as 
DALYsSB(r,K,A).  Notation around YLL is similarly extended. 
 
Explicit modeling of ALP permits three instrumentally useful improvements to the previous 
formulation of DALYs: 
•  The DALY from a death seconds before birth is, in the previous formulation, 0; it jumps 
to more than 30 years at birth. The ALP formulation allows, but does not require, this 
discontinuity to be avoided.    
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•  The ALP formulation allows, but does not require, DALYs to be associated with 
stillbirths. 
•  The ratio of the DALY from a death at age 20, say, to that at birth is close to 1 for any 
reasonable set of parameter values in the previous DALY formulation.  Many people’s 
ethical judgments would give this ratio a value substantially greater than 1.  The ALP 
formulation allows, but does not require, these judgments.  
 
  Only a limited number of empirical studies have attempted to assess directly the views of 
individuals concerning deaths at different ages.  In an important early study, Crawford, Salter, 
and Jang (1989) relate grief from a death to the concept of reproductive potential as a function of 
age in population biology.  (This is the expected number of offspring a person will have after a 
given age given the fertility and mortality rates.)  They conclude that for several diverse human 
groups the relationship shows grief to be closely related to reproductive value at the age of death 
when calculated for high mortality and high fertility populations for hunter-gatherer populations.  
An Institute of Medicine (1985) review of vaccine development priorities uses infant mortality 
equivalence in cost-effectiveness calculations. The committee members preparing the report 
collectively judged that the loss from a death at age 20 should be about two times that from an 
infant death.  However, some preliminary trade-off studies suggest a value closer to three or four 
times.  All three lines of evidence point to gradual rather than instantaneous ALP.  What is clear, 
however, is that no completely defensible estimate (or even range) is currently available, and 
hence the numbers used in Jamison, et al. (2006) should be viewed as only suggestive.  Table 5 
shows the YLLs associated with deaths at different young ages for alternative formulations of the 
DALY, including one with their preferred value of A = .54 .  This final column reports several 
estimates.  (It is important to note that DALYs and YLLs for deaths above age 5 are unaffected 
by introduction of ALP.)  Weighting the YLLs at different ages by the relative frequency of 
deaths at those ages gives a DALYSB (3,0, .54) loss of 16.4 DALYs for a typical under-5 death, 
about half what is typically used.  Our analyses use this figure.  
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age of death 
(years)  YLL(3,1)  YLL(3,0)  YLLSB(3,0,1)  YLLSB(3,0,.54) 
Antepartum  –0.080  0  0  30.42  4.95 
Intrapartum  –0.001  0  0  30.42  9.13 
Neonatal  0.020  33.09  30.42  30.42  9.40 
Infant  0.300  33.36  30.40  30.40  12.95 
Postneonatal infant  0.500  33.56  30.39  30.39  15.42 
Child  2.000  34.81  30.28  30.28  26.40 
Source:  Jamison, et al. (2006), Table 6.6. 
Note:  YLL(3,1), YLL(3,0), and YLLSB(3,0,1) assume instantaneous acquisition of life potential, ALP (A = 1). YLL(3,1) assumes full age 
weighting (K = 1); the other three formulations assume uniform age weights (K = 0). YLLSB(3,0,.54) assumes gradual acquisition of life 
potential (A = .54).  The subscript SB refers to formulations that do not give stillbirths zero weight.   




3.3  The Value of an Averted DALY 
 
  The VSL estimates discussed in Section 2.2 yield a range of values for a statistical life—
from around 100 to almost 200 times per capita income.  Very approximately this can be 
translated to a value for a statistical life year (VSLY) in the range of 2 to 4 times per capita 
income.  Tolley, Kenkel and Fabian (1994) provide a valuable overview of relevant estimates, 
including estimates of the value of preventing disability. The emphasis in this paper is on low-
income countries, defined by the World Bank for 2001 as countries with per capita incomes of 
less than $745 (exchange rate).  The World Bank’s estimate of the average income of people 
living in low-income countries is $585 per year (World Bank, 2007).  Choosing a value for a 
VSLY at the low end of the range (a little below 2) would give a convenient value of $1,000, 
which is what this paper uses in its main calculations as the value of a DALY.  (Note that for the 
reasons discussed in Section 3.2 the DALY from a death under age 5—and hence the benefit 
from preventing it—is about half that used in standard DALYs.)  In Appendix B explore the 
sensitivity of our results to these assumptions by using a DALY value of $5000 and by using 
standard DALYs (DALYs (3,0)) for child deaths. For some conditions, for example anemia and 
the intestinal worm infections, the resulting loss in economic productivity is likely to be 
understated in the disability component of the DALY.  In these cases we will be underestimating 
total benefits. 
 
  3.4 The Cost of an Averted DALY   
  The cost of buying an averted DALY with different interventions was calculated, in 
DCP2, by combining ‘typical’ prices for a geographical region (Mulligan, et al. 2003) with input 
quantities estimated from clinical and public health experience and case studies in the literature.  
For internationally traded inputs, prices were the same for all regions. (Because of tiered pricing, 
off-patent drugs were not considered to be internationally traded.)  For local costs, regional 
estimates were used.  Intervention costs, therefore, are not expressed in PPP dollars.  The reason 
for this is that local costs present decision-makers with the appropriate numbers for budgeting 
and for comparing interventions in the context where they are working.  (Regional costs are  
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taken to be a better approximation of local costs than global costs would be.)  On this point the 
methods of this paper differ from those of its predecessor (Mills and Shilcutt, 2004).   
 
4.  CHILD HEALTH 
 
A small number of conditions accounts for most of the (large) differences in health 
between the poor and the not so poor.  Almost 60% of the difference in DALY rates between 
low- and middle-income countries on the one hand and high-income countries on the other is due 
to the following conditions: malaria, diarrhea, acute respiratory infections, vaccine-preventable 
diseases and perinatal conditions.  These are essentially childhood conditions.
7 Available 
technical options—exemplified by but going well beyond immunization—can address most of 
the conditions that affect children, and can do so with great efficacy and at modest cost.  That 
short list of conditions, including micronutrient undernutrition, relates directly to achieving the 
MDGs for health. Public expenditures to address those conditions have, in the past, benefited the 
relatively well off, albeit within poor countries (although global inequities in health have 
decreased because many poor countries have made much progress). 
 
4.1  Under-5 Health Problems and Intervention Priorities 
 
The Millennium Development Goal for under-5 mortality (MDG-4) (reducing its level in 
2015 by two-thirds relative to what it was in 1990) is highly ambitious. Yet its implication of an  
average 4.3 percent per year decline is well within recent experience.  In the first half of the 
MDG period (1990–2002), 46 countries achieved rates of decline in under-5 mortality greater 
than 4.3 percent per year (Lopez, Begg and Bos, 2006).  
Basic knowledge about the power and the cost-effectiveness of interventions to address maternal 
and child health has been available since the 1980s. DCP2’s work makes four important 
relatively new points. First, major declines in childhood mortality could well be accelerated with 
expanded case-management of acutely-ill children and with the addition of several new vaccines 
to the to the routine immunization schedule.  These include those that protect against 
                                                 
7 By adding TB and AIDS to this list 75% of the difference would be accounted for.  
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Haemophilus influenza type b (Hib) and Streptococcus pneumoniae, which are common causes 
of childhood pneumonia; hepatitis B, which tends to cause liver cancer; and rotavirus and 
shigella, which cause diarrhea (England et al, 2001).  The Global Alliance for Vaccines and 
Immunization (GAVI) estimates that the addition of Hib and pneumococcal vaccines to 
vaccination programs could save 800,000 lives a year by 2010.  Further GAVI estimates suggest 
that rotavirus and shigella vaccines might save 600,000 by 2010.  Bloom, Canning, and Weston 
(2004) report rates of return to investment in basic vaccine packages of 12-21% 
Second, as noted earlier, half of under-5 deaths occur at ages less than 28 days, when the 
substantial but usually neglected problem of stillbirth is considered.  DCP2 identifies some 
highly cost-effective approaches to intervention against stillbirth and neonatal death (Lawn et al., 
2006).   
Third, there is a rapid spread of resistance of the malaria parasite to chloroquine and to 
sulfadoxine-pyrimethamine (SP).  These inexpensive, highly effective, widely available drugs 
provided an important partial check on the high levels of malaria deaths in Africa, which are 
concentrated particularly in children.  Their loss is leading to a rise in malaria mortality and 
morbidity that could be substantial.  Figure 4 illustrates increases in malaria death rates and 
decreases in death rates from other causes except AIDS in under-5 children in Sub-Saharan 
Africa in the period from 1990 to 2001.  (This increase in malaria mortality rates results in 
hundreds of thousands of deaths more than would otherwise have occurred.)  The design of 
instruments for financing a rapid transition to appropriate treatments—in particular, artemisinin 
combination therapies (ACTs)—is a high priority (Institute of Medicine, 2004; Arrow, Gelband, 
and Jamison 2005). The principal development assistance modality proposed – the Affordable 
Medicines Facility-malaria (AMFm) – aims to reduce the relative prices countries face for ACTs 
rather than to increase their budgets for purchasing them. 
Fourth, although education interventions are considered in a separate paper for 
Copenhagen (Orazem, 2007), it is worth noting in the context of considering alternatives for 
reducing child mortality that improvements in the quality of basic education can plausibly have 
benefit-to-cost ratios as high as for many health interventions – even if no benefits of education 
other than mortality reduction are included.  (By “quality” of education, we refer narrowly to 
quality as reflected in scores on internationally standardized achievement tests, particularly those 
in mathematics.)  In a recent paper, Jamison, Jamison, and Hanushek (2007) estimate that the  
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effect of a one standard deviation improvement in quality would increase the annual rate of 
decline of infant mortality by about 0.6 percentage points, e.g., from a rate of decline of 2% to 
2.6% per year, leading, after 20 years, to something over a 10% reduction in IMR relative to 
what it would otherwise have been.  They estimate that this effect could be achieved for roughly 
10% of the cost of a year of schooling, which is likely to be less than $100 per student per year in 
a low-income country.  If the total fertility rate is 3 and the base level of IMR is 70 per 1000, 
then education quality improvement is likely to result in a cost per (undiscounted) child death 
averted of around $1000.  Assuming, as this paper does, a low DALY per child death of about 16 
and the value of a DALY in low income countries to be $1000, then the B:C ratio will be about 
13.  Discounting the benefits at 6% gives a B:C of 4, again ignoring any other benefits from the 
education. Increasing the value of averting a DALY from $1000 to $5000 would increase the 
B:C ratio to 20, even with 6% discounting.  Using the estimated effects of a year of schooling 
from the same paper, the B:C for increasing the quantity of schooling by one year is 0.6 or (3 
with $5000 DALYs), ignoring other benefits. 
In addition to the above, other intervention priorities for addressing under-5 mortality are 
for the most part familiar:  
•  Maintain an emphasis on exclusive early breastfeeding, which has increased widely in all 
parts of the world over the last few years. 
•  Expand immunization coverage of the current set of antigens in the Expanded Program 
on Immunization (EPI). 
•  Add new antigens— HiB, hepatitis B, rotavirus and streptococcus—to the EPI schedule. 
•  Expand the use of the simple and low-cost but highly effective treatments for diarrhea 
and child pneumonia through integrated management of childhood illness or other 
mechanisms. 
•  Prevent transmission of and mortality from malaria by expanding coverage of insecticide-
treated bednets, by expanding use of intermittent preventive treatment for pregnant 
women, and by use of indoor residual spraying with DDT and other insecticides. 
•  Ensure widespread distribution of key micronutrients, most notably Vitamin A, zinc, and 
iron. 
•  Expand the use of antiretrovirals and breast feeding substitutes to prevent mother-to-child 
transmission of HIV.  
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Figure 4    Under-5 Deaths from AIDS, Malaria,  
   and Other Causes, per Thousand Births, 1990 and 
   2001, Sub-Saharan Africa 
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In addition to interventions to reduce under-5 mortality, one other priority is clear.  The 
world’s most prevalent infections are intestinal helminth (worm) infections, and children of all 
ages are the most heavily affected.  Warren, Bundy et al (1993) review and a range of 
experimental studies of the effectiveness of mass drug administration (in high prevalence 
environments) and estimate quite attractive cost-effectiveness ratios.  Hotez, et al. (2006) provide 
a more up to date discussion of these infections and related interventions. Bundy, et al. (2006)’s 
discussion of school health services points to both the importance to children’s school progress 
of taking albendazole where needed and the potential efficacy of school health programs as a 
vehicle for delivery. In the long run, improved sanitation and water supplies will prevent 
transmission. Use of albendazole is only an interim solution, but it is one that may be required 
for decades if the experience of the currently high-income countries is relevant, and its benefits 
relative to costs appear high. 
 
4.2  Delivering Child Health Interventions 
 
The list of potential interventions is far from exhaustive, and different regions, countries, 
and communities will face different mixes of the problems these interventions address.  
However, there can be little dispute that any short list of intervention priorities for under-5 
mortality in low- and middle-income countries would include many on the list in the preceding 
section. Why not, then, simply put money into scaling up these known interventions to a 
satisfactory level? 
To greatly oversimplify—and these issues are discussed more substantially in Mills et al. 
(2006)—two schools of thought exist.  One line of thinking—often ascribed to macroeconomist 
Jeffrey Sachs and his work as chair of the WHO CMH—concludes that more money and focused 
effort are the solutions.  Although acknowledging dual constraints—of money and of health 
system capacity—Sachs and his colleagues (WHO CMH 2001; Sachs 2005) contend that money 
can buy (or develop, or both) relevant system capacity even over a period as short as five years. 
Major gains are affordable and health system capacity constraints can be overcome.  
Immunization provides an example of where, even in the short term, money can substitute for 
system capacity.  Adding newer antigens to the immunization schedule is costly (although still 
cost effective).  In some environments, however, it proves less demanding of system capacity  
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than expanding coverage does.  Money can be effectively spent by adding antigens at the same 
time as investing in the capacity to extend coverage.  The newly established International 
Finance Facility (IFF), and the Global Alliance for Vaccines and Immunization (GAVI) are 
recently established institutional innovations to speed global immunization coverage. 
A second school of thought acknowledges the need for more money but asserts that 
health system capacity is often a binding short- to medium-term constraint on substantial scaling-
up of interventions.  Van der Gaag (2004) emphasized this point in his critique of an earlier 
Copenhagen Consensus paper on health.  Critical priorities are, therefore, system reform and 
strengthening while ensuring that such reforms focus clearly on achieving improved health 
outcomes and financial protection.  
This paper’s perspective is closer to that of Sachs than of Van der Gaag while 
emphasizing the need (in Section 3.1) to be explicit about intervention costs that are 
nonfinancial.  This points both to the need for considering how to reduce such costs nonfinancial 
costs and to select interventions in part by the extent to which they are less demanding of 
nonfinancial inputs. Sepúlveda (2006) and others have described the “diagonal” approach being 
used in Mexico, where systems are strengthened while focusing on specific disease outcomes.  
Experience suggests that although such an approach demands considerable management, it is 
highly effective.  Against a backdrop of low immunization coverage in Africa, Malawi, one of 
the poorest countries in the world, has succeeded in boosting immunization coverage against 
measles from only 50% in 1980 to almost 90% today.  Malawi undertook a program to raise 
routine measles immunizations, including campaigns to catch children missed by routine efforts.  
As a result, the number of reported cases and deaths has fallen dramatically. During 1999, only 
two laboratory-confirmed cases were reported. And, for the first time ever, there were no 
measles deaths. Yet only two years earlier, almost 7000 measles cases and 267 deaths (both of 
which are likely to be undercounts) were reported.  This reduction was achieved despite 20% of 
the population not having access to health services, less than 50% having access to safe water, 
and only 3% having access to adequate sanitation. (Jha and Mills, 2002). 
Mills et al. (2006), as indicated, discussed these issues further in the context of all the 
problems facing a health system.  From an individual country’s perspective, however, if financial 
resources are available, the question is very much an empirical one:  to what extent can those 
resources be effectively deployed in buying interventions, in buying out of prevailing system  
36 
constraints, and in investing in relevant system capacity for the future?  Accumulating 
experience suggests that to be successful, these choices will involve focused attention and 
sustained funding to achieve specific outcomes (Jha et al, 2002; Crogan, 2006).  
 
5.   HIV/AIDS and Tuberculosis 
 
For dozens of countries around the world—including several of the most populous—the 
HIV/AIDS epidemics threaten every aspect of development.  Most governments of affected low- 
and middle-income countries and most providers of development assistance have only recently 
begun to respond more than minimally.  Creation of the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria can be viewed as an attempt by the world’s top political leaders to 
improve on the records of existing institutions.  The Global Fund’s initial years have seen 
substantial success, but that success is potentially undermined by constraints on resource 
availability (Bezanson 2005). 
In contrast to the initially slow programmatic movement of most national leaders and 
international institutions, the research and development community—public and private—has 
made rapid progress in developing tools to control the HIV/AIDS epidemic, although both a 
vaccine and a curative drug remain distant objectives.  Sensitive, specific, and inexpensive 
diagnostics are available; means of prevention have been developed and tested; modes of 
transmission are well understood; and increasingly powerful drugs for controlling viral load 
allow radical slowing of disease progression.  Tools for dealing with HIV/AIDS are thus 
available:  Bertozzi and Padian (2006) emphasize that a number of countries show by example 
that those tools can be put to effective use.  Most of the high-income countries have done so, and 
Brazil, Mexico and Thailand provide examples of upper-middle-income countries that have 
forestalled potentially serious epidemics (del Rio and Sepúlveda 2002).   
  This section first discusses prevention and then antiretroviral therapy.  It closes with a 
discussion of tuberculosis, both as an opportunistic infection of AIDS and a major global 
problem in itself.  
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5.1  Prevention of HIV Transmission 
 
The HIV/AIDS pandemic is undoubtedly the most dramatic health challenge facing the 
world. HIV has reached every country in the world.  In southern and eastern Africa, infection is 
running at unprecedented levels.  However, the epidemic looks very different in different places.  
The dominant form of transmission worldwide is heterosexual, with other modes—the use of 
injected drugs and sex between men—being important in several regions.  Three broad 
epidemiological patterns can be discerned.  In eastern and southern Africa, the disease has spread 
quickly and widely throughout the population.  HIV prevalence in antenatal clinic attendees 
doubled from 18% to 30% in Botswana from 1994 to 2005; in South Africa this increased from 
3% to 15% over the same time period.  A few other countries in Africa have shown substantial 
but less dramatic increases to prevalence rates over 3%.  The remaining African countries, and 
almost every other country in the world, have adult prevalence rates below 3%. 
The reasons for the variations in prevalence between countries are not entirely clear and 
poorly researched.  It is now clear that high levels of male circumcision protect against HIV 
transmission at the population and individual level (Abdool Karim, 2007).  High levels of genital 
ulcer disease and low levels of male circumcision may help to explain the high HIV levels seen 
in southern and eastern Africa.  However, conditions rife for rapid growth exist in many places.  
These conditions include high levels of paid sex and partner change, high prevalence of sexually 
transmitted infections (STIs), low condom use rates, male mobility and migration, and low rates 
of male circumcision.   
The key challenge for HIV/AIDS policy is to prevent HIV transmission. In the absence of 
a vaccine, several interventions are of key importance.  The most clearly effective preventive 
interventions against HIV are those targeting groups that—because of high rates of partner 
change, increased susceptibility to infection, or both—are highly vulnerable (Chen, et.al., 2007).  
Peer interventions among sex workers to teach them high levels of condom use, control of STIs, 
and client negotiation skills are effective.  Less than one sex worker would need to be covered in 
a program for one year to prevent one infection (Jha et al, 2001). 
A few countries in Asia with conditions for rapid growth in HIV-1 infections acted early 
by scaling up interventions in vulnerable groups.  Their common principles were to work with  
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the commercial sex industry, map where infection occurs, aim for high coverage, and base action 
on solid epidemiological information.  The results are impressive.  Thailand is the most famous 
example, where HIV-1 peaked in the early 1990s and has stayed at below 2% seroprevalence 
since.  Less known are Mexico (del Rio and Sepúlveda, 2002) and Cambodia, which copied the 
Thai “100% condom” program in commercial sex in 1997 in one state, and has shown 
impressive declines in HIV-1.  More recent evidence from the four southern states of India 
suggest that new HIV infections might have dropped by 50%, probably due to changes in sex 
work (either the proportion using condoms or men going less often to sex workers; Kumar et al, 
2006). Other interventions that complement vulnerable group interventions are effective.  
Despite controversy, STIs remain important as risk markers and risk factors for the spread of 
HIV.  STI treatment for vulnerable and general populations is probably effective for HIV control.  
Voluntary counseling and testing has led to some reduction in unsafe behavior in some studies, 
though the duration of the change is not clear.  However, such testing is not necessarily a cost-
effective form of prevention in all or even most settings, especially where prevalence is low.  
Voluntary testing is, however, a necessary prerequisite to some forms of treatment. 
Although the transmission of HIV from mother to child is not of great epidemiological 
importance, since the infected children are very unlikely to transmit the disease, it is a mode of 
transmission that can be blocked, and which currently accounts for perhaps half a million deaths 
a year.  Short courses of single antiretrovirals can halve transmission risk from about 40% to 
20%.  To be fully effective, replacement feeding is also required, given that breast milk is a 
source of transmission.  Finally, needle exchange programmes and blood safety programmes can 
reduce these less common modes of transmission.  More broadly, prevention efforts appear to 
work best when there is national leadership and simultaneous, sustained investment in multiple 
approaches to prevention, including efforts to reduce stigmatization of vulnerable groups.  
Increasing the availability of condoms for the wider population can enable more focused action.  
For example, the proportion of Senegalese women easily able to procure condoms rose from 
below 30% to 80% between 1992 and 1997.  Focused information campaigns aimed at building 
public support and awareness are important, although these are not likely to change behavior in 
the absence of complementary preventive measures. 
In those sub-Saharan countries with generalized epidemics that have spread far beyond 
vulnerable groups, a national approach is necessary.  The reasons for the sharp decline in HIV  
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prevalence in Uganda, from about 20% in 1990 to 10% in 1999, are widely debated.  It may be 
due, at least in part, to a broad-based prevention strategy addressed at the population as a whole, 
or simply to the fact that high death rates among those infected helped the epidemic to decline 
(James 2005). The replicability of the Ugandan experience to lower-prevalence settings is not 
established.   
Bertozzi, Padian et al. (2006) point out that even by 2003 fewer than one in five people at 
high risk of infection had access to the most basic preventive services.  In much of the world, 
little has been spent on prevention, and little has been achieved.  In addition, the current U.S. 
administration may be partially responsible for discouraging condom use in some countries and 
in stigmatizing and alienating commercial sex workers, who are particular priorities for 
prevention programs.  Despite those problems, the potential for prevention is very real, and a 
number of successful countries have shown the possibility of using that potential well.  Piot, et 
al. (2008, forthcoming) summarize experience to date by observing that although evaluations of 
single interventions have often failed to find an impact, the countries that have mounted major 
programs of “combination prevention” have often achieved substantial success. The ingredients 
in the combination cocktail vary by location, but there is now reasonable evidence for its general 
success. 
In addition to prevention, better management of patients with AIDS could avert much 
misery, both by treating opportunistic infections and by alleviating the often excruciating pain 
associated with many AIDS deaths.  Medically inappropriate restrictions on the use of 
inexpensive but powerful opiates for pain control continue to deny dignity and comfort to 
millions of patients with AIDS and cancer in their final months (Foley et al. 2006). 
 
5.2  Antiretroviral Treatment of AIDS 
 
A primary focus on prevention strategies in the global response to HIV/AIDS reflects the 
fact that the future of the pandemic lies with those not yet infected.  However, this cannot be 
taken as a reason to neglect the 35-40 million people currently living with the infection, 95% of 
them in low- and middle-income countries.  Prophylaxis or treatments for some of the 
opportunistic infections that contribute to HIV/AIDS mortality are cost-effective (most notably 
antibiotics effective against TB).  Since 1996, highly active anti-retroviral therapy (HAART),  
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which acts directly on the virus, has increased the life expectancy of people on treatment 
considerably.  In developed countries, HAART has dramatically reduced but not eliminated 
AIDS mortality.  Reduction in viral load slows or halts progression of AIDS and can return 
individuals from serious illness to reasonable health.  Available drugs leave a residual population 
of HIV in the body, however, and this population grows if the drugs are stopped.  At present the 
drugs must be taken for life.  Widespread use of these drugs in high-income (and some middle-
income) countries has transformed the life prospects of HIV-infected individuals. 
Early-generation antiretroviral drugs suffered notable shortcomings:  they were 
enormously costly; regimens for their use were complicated, making adherence difficult; their 
use generated unpleasant side effects; and rapid evolution of HIV led to resistant mutants that 
undermined the efficacy of therapy.  In a remarkably short time scientific advances have 
substantially attenuated those problems, making feasible, at least in principle, antiretroviral 
therapy in low-income settings.  WHO’s “3 by 5” program had as its objective, for example, to 
reach 3 million people in low- and middle-income countries with antiretroviral therapy by 2005. 
Although that goal was far from being met, the global effort to make treatment widely available 
is well under way.  An important contributor has been the Clinton Foundation’s effort to 
negotiate reductions in the prices of first-line drugs and, more recently, second-line drugs.  
Despite the indicated progress against the problems with antiretroviral drugs, challenges 
to their effective use in low-income environments remain formidable.  The complexity of patient 
management is very real.  Management requires high levels of human resources and other 
capacities in many of the countries where those capacities need to be most carefully rationed. 
Perhaps in consequence, achieving effective implementation has been difficult on even a limited 
scale.  Bertozzi and Padian et al. (2006) review those problems and how they might be 
addressed. 
Three points concerning widespread antiretroviral drug use are particularly noteworthy: 
•  Poor implementation (low adherence, development of resistance, interruptions in drug 
supplies) is likely to lead to very limited health gains, even for individuals on therapy.  
(This outcome is unlike that of a weak immunization program in which health gains still 
exist in the fraction of the population that is immunized.)  Poorly implemented 
antiretroviral drug delivery programs could divert substantial resources from prevention 
or from other high-payoff activities in the health sector.  Even worse, they could lead to a  
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false sense of complacency in affected populations: evidence from some countries 
suggests that treatment availability has led to riskier sexual behavior and increased HIV 
transmission.  The injunction to “do no harm” holds particular salience. 
•  Unless systematic efforts are made to acquire hard knowledge about which approaches 
work and which do not, the likelihood exists that unsuccessful implementation efforts 
will be continued without the appropriate reallocation of resources to successful 
approaches.  Learning what works will require major variations in approach and careful 
evaluation of effects.  Failing to learn will lead to large numbers of needless deaths.  
Most efforts to scale up antiretroviral therapy unconscionably fail to commit the 
substantial resources required for evaluation of effects.  Such evaluations are essential if 
ineffective programs are to be halted or effective ones are to receive more resources. 
•  Many programs rely exclusively on the cheapest possible drugs, thereby risking problems 
with toxicity, adherence, and drug resistance.  From the outset a broader range of drug 
regimens needs to be tested. 
Use of antiretrovirals (ARV) are likely to have a B:C ratio greater than 1 in many circumstances.  
However if such use competes with other highly attractive health investments in environments 
with limited human and financial resources, widespread adoption needs to be carefully 
sequenced. 
 
5.3  Control of Tuberculosis 
 
Tuberculosis is the leading cause of adult death from infectious disease after HIV/AIDS. 
Nearly 9 million new cases and perhaps 1.6 million deaths were caused by tuberculosis globally 
in 2003, with over 90% of these in low- and middle-income countries. Tuberculosis, like 
HIV/AIDS, causes deaths during the productive working age, and can thus trigger household 
poverty. Only a small percentage of those infected with the tuberculosis bacillus go on to active 
disease such as pulmonary tuberculosis. Key risk factors for active tuberculosis include poverty, 
household crowding, and smoking (Pai et al, 2006).   
 
TB can be controlled by preventing infection, by stopping progression from infection to 
active disease, and by treating active disease. The principal intervention is the “DOTS” strategy  
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and its variations, centered on the diagnosis and treatment of the most severe and most infectious 
(smear-positive) forms of TB but including treatment for smear-negative and extrapulmonary 
cases as well.  Anti-TB drugs can also be used to treat latent M. tuberculosis infection and active 
TB in patients with HIV coinfection, and the widely used bacillus Calmette-Guérin (BCG) 
vaccine prevents (mainly) severe forms of TB in childhood (Dye et al, 2006).  The cornerstone of 
TB control is the prompt treatment of active cases with short-course chemotherapy using first-
line drugs, administered through the DOTS (directly observed treatment, short course strategy), 
which has five elements: (i) political commitment; (ii) diagnosis primarily by sputum-smear 
microscopy among patients attending health facilities; (iii) short course chemotherapy with three 
to four drugs including effective case management (including direct observation of treatment); 
(iv) a regular drug supply; and (v) systematic monitoring to evaluate the outcomes of every 
patient started on treatment. 
 
The MDGs call for halting and beginning to reverse new cases of TB by 2015 and the 
Stop TB Partnership calls for halving prevalence and deaths by 2015 relative to 1990 rates. It has 
been estimated that these goals can be reached if 70% of new infectious (smear positive) cases 
worldwide are detected and 80% of those cases are treated successfully with the DOTS regime.  
“high burden countries”, and progress has been impressive.  The case detection rate has 
increased from 11% globally in 1996 to 53% in 2004, and over 21 million TB patients were 
treated in DOTS programs in the decade since 1994.  China and India have been noted as having 
particularly strong programs—although rigorous evaluation of the mortality impact of TB 
programs awaits.  Key challenges remain the spread of HIV infection in parts of Africa and drug 
resistance, especially in Eastern Europe.  This suggests that DOTS alone might not be able to 
bring TB under control, especially in Africa and in the countries of the former Soviet Union.  
 
The cost-effectiveness of tuberculosis control has been well established (summarized in 
Dye et al, 2006), but more recently Laxminarayan et al (2007) have calculated the cost-benefit of 
the WHO DOTS strategy at current levels relative to having no program in place.  The ratio of 
marginal benefits to costs of implementing a global plan for DOTS is over 15 in the 22 ‘high-
burden’ countries, and 9 in the Africa region.  
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6.   NONCOMMUNICABLE DISEASE 
 
At the same time that most low- and middle-income countries need to address health 
problems that are now effectively controlled in high-income countries, they are increasingly 
sharing the high-income countries’ heavy burdens of cardiovascular system disease, cancers, 
respiratory diseases, psychiatric disorders, and automobile-related injuries.  DCP2 has chapters 
addressing each of these NCDs and others.  The public health research and policy community 
has been surprisingly silent about these epidemics even though, for example, cardiovascular 
disease (CVD) in low- and middle-income countries killed over twice as many people in 2001 as 
did AIDS, malaria, and TB combined (see Table 4 for data on causes of deaths over age 5).  An 
important early exception was Feachem and others (1992), who indicated approaches to 
treatment and prevention of these conditions that can be adapted to the tighter budget constraints 
of developing countries.  The World Health Organization provides a valuable and more up-to-
date discussion that emphasizes prevention (WHO, 2005).  In addition, low-cost but effective 
approaches to long-term management of chronic conditions need to be developed and 
implemented, as was emphasized in a recent World Bank policy review (Adeyi, Smith and 
Robles, 2007). The challenge, as with so many other efforts to improve public health, is to 
identify approaches that provide genuine benefit in response to major sources of disease burden 
while costing sufficiently little that they can become (over time) universally available within the 
very tight public expenditure constraints of developing countries. 
The remainder of this section briefly discusses, as examples, the prevention and 
management of cardiovascular diseases, and smoking as a risk factor for multiple NCDs. 
 
6.1  Cardiovascular Disease 
 
Cardiovascular diseases in low- and middle-income countries result in about 13 million 
deaths each year, over a quarter of all deaths in those countries.  Most cardiovascular deaths 
result from ischemic heart disease (5.7 million) or cerebrovascular disease (4.6 million).  (A 
potentially substantial fraction of the heart disease deaths may result from congestive heart 
failure.)  In all countries, these deaths occur at older ages than do infectious conditions and thus 
account for a substantially smaller fraction of total disease burden in disability-adjusted life years  
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(DALYs)—12.9 percent—than they do of deaths.  However, a far greater proportion of the 
cardiovascular deaths in low- and middle-income countries occur in middle age (30-69) than 
they do in high-income countries, where they are concentrated at older ages.  
The main risk factors for CVD account for very large fractions of the deaths (and even 
more of the burden) from those diseases.  For ischemic heart disease, they collectively account 
for 78 percent of deaths in low- and middle-income countries; for stroke, they account for 61 
percent (Ezzati and others 2006).  Measures to reduce the levels of those risk factors—high 
blood pressure, high intake of saturated animal fat, smoking, obesity, binge drinking of alcohol, 
physical inactivity, and low fruit and vegetable consumption—are the main means of prevention.  
Unlike the favorable experience with controlling tobacco use, attempts to change behaviors 
leading to obesity, hypertension, adverse lipid profiles, or physical activity appear to have had 
little success at a population level.  A notable exception is the remarkable 25% decline in 
vascular mortality in the 1990s in Poland, which appears due to macroeconomic reforms that 
effectively removed the government subsidy for butter overnight, and simultaneously opened up 
markets from Western Europe of fresh fruits and vegetables, as well as products with lower 
amounts of saturated fat (Zatosnki et al, 2001). As Willett et al. (2006) document, many 
promising approaches remain to be tried.  Common sense suggests that they should be initiated 
even while more systematic efforts to develop and evaluate behavior-change packages are 
ramped up. 
Pharmaceutical interventions to manage two major components of cardiovascular risk—
hypertension and high cholesterol levels—are well established and are highly cost-effective for 
individuals at high risk of a stroke or heart attack.  Adding aspirin to the list of pharmaceutical 
interventions can reduce risk significantly further.  From at least the time of publication of 
DCP1, researchers have recognized that the low cost and high effectiveness of drugs to prevent 
the reoccurrence of a cardiovascular event made their long-term use potentially cost-effective in 
low-income environments (Pearson, Jamison and Trejo-Gutierrez).  Even if sustained behavior 
change proves difficult to achieve, medications have the potential to reduce CVD risks by 50% 
or more.  Simple combinations of cheap drugs can be highly effective in reducing mortality 
among the millions of adults worldwide who already have some form of vascular disease or 
diabetes diagnosed. For example, among patients with a history of occlusive vascular disease 
such as stroke or heart attack, use of aspirin, a statin and an antihypertensive drug could reduce  
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the annual risk of major recurrence by about two-thirds; the 10-year risk of death or readmission 
to hospital is about 50% if people go untreated but only 16% if they receive daily treatment with 
three or four drugs (Peto et al, 2001). 
  All of these drugs are inexpensive and could easily be packaged into “polypills” or 
“generic risk pills” for widespread use. Gaziano et al. (2006) and Rodgers et al. (2006) develop 
the current evidence on that point. A key problem, however, concerns the health care personnel 
and systems requirements associated with the need for lifelong medication—a problem also 
faced with antiretroviral therapy for AIDS and the use of medications to target several major 
psychiatric disorders.  Adherence to drugs is a key issue, but unlike the challenge with AIDS 
drugs, resistance to use of the polypill drugs is unlikely, and their costs are quite low.  (These 
problems illustrate the importance of the nonfinancial costs discussed in Sections 3 and 4 and 
related issues of health system development.)  How to achieve effective long-term management 
of lifesaving drugs is a key delivery and research challenge for health system reformers.  
In contrast to the lifelong requirement for drug use associated with CVD risk reduction in 
high-risk individuals, treatment of acute heart attacks with inexpensive drugs is both less 
demanding of system resources and highly cost-effective (Gaziano et al., 2006).  Given the high 
incidence of these problems, system-wide efforts to achieve high rates of appropriate drug use in 
response to acute heart disease are a high priority. 
 
6.2  Tobacco Addiction 
 
In most low-income countries, death in middle age increases in relative frequency as the effects 
of smoking increase.  Most adult deaths worldwide involve vascular, neoplastic and respiratory 
disease, and smoking makes each of these more common.  However, tobacco kills differently in 
different parts of the world. In China, the leading causes of death from smoking are chronic lung 
disease and lung cancer, with a noted excess also of tuberculosis deaths but relatively little heart 
disease (Liu et al, 1998).  In India, the leading causes of death from smoking are tuberculosis in 
rural areas and acute heart attack in urban areas, with lung cancer less common (Jha et al, 2008). 
In 2001, the number of tobacco-related deaths in developing countries was estimated to 
be 3.34 million or about 9% of deaths over age 5 in these countries (Lopez, et al., 2006).  
However, extrapolating from current patterns, tobacco use may account for some 10 million  
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deaths per year by 2030, with most of these occurring in low- and middle-income countries.  In 
total, some 1 billion tobacco deaths might occur this century in contrast to 100 million in the 20
th 
century.  Unless there is widespread cessation of smoking, some 100 million of China’s 200 
million young male smokers and about 40 million of India’s 100 million young male smokers 
will eventually die from tobacco-related causes. Smoking is already more common among poor 
or uneducated males than among richer or educated males, and smoking mortality accounts for 
about half of the difference in mortality risk between rich and poor men in Western countries 
(Jha et al, 2006b). 
 
Preventing the initiation of smoking is important because addiction to tobacco makes 
smoking cessation very difficult, even for the numerous individuals who would like to do so.  
However, helping people quit smoking is at least as important as preventing initiation for there to 
be effects on mortality sooner than the very long run.  Figure 5 portrays estimates showing that 
far more lives could be saved between now and 2050 with successful efforts to help people stop 
smoking than with efforts to keep them from starting. Reducing smoking levels is well 
demonstrated to be within the control of public policy.  Indeed, many OECD countries have seen 
substantial declines in smoking deaths over the past two decades; for example, lung cancer 
deaths among young men 30–44 years of age have fallen by nearly 80% in the United Kingdom 
(Peto et al, 2003), a change attributable chiefly to marked increases in cessation. Also, in OECD 
countries more than 30% of the adult population are ex-smokers, in contrast to only 2% in India, 
9% in China and 15% in Thailand (Jha et al, 2006a). Tobacco tax increases, dissemination of 
information about the health risks of smoking, restrictions on smoking in public and work places, 
comprehensive bans on advertising and promotion, and increased access to cessation therapies 
are effective in reducing tobacco use and its consequences (Jha et al, 2006a). Of these, taxing 
tobacco is particularly effective, with a 10% increase in price leading to a 4 to 8% drop in 
consumption (roughly equally split between cessation and initiation).  Young people and the 
poor are particularly responsive to price (Jha and Chaloupka, 2000).  
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      Source:  Jha, et. al., 2006a. 
 
 
       Figure 5    Increase in Tobacco-Related Deaths as 
     Populations Age 
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Tobacco use is substantially different from other health challenges as it involves use of a 
consumer good, with presumed economic benefits from that consumption.  This has led to 
criticisms that tobacco control ignores the welfare benefits of smoking (Wolf 2006).  This is no 
doubt to some extent correct although measurement of welfare gains from an addictive substance 
is complex (Sen 2007).  It is clear that among informed tobacco users there is a widespread 
desire to quit smoking, and willingness to pay for help with cessation at the same time that 
money is being spent on tobacco. 
Of more importance is the widespread ignorance of risks. In China in 1996, 60% of adult 
smokers thought that smoking did little or no harm.  Indeed, the recent increase in cessation in 
China might be related to new information on tobacco risks published in the late 1990s (Jha and 
Chen, 2007).  In most countries with good information on tobacco risks, over three-quarters of 
adult smokers regret ever having started as adolescents.   
Putting addiction into a cost-benefit framework is therefore tricky. Peck et al (2000) built 
on an earlier framework by Barnum (1993) by comparing the consumer and producers surplus of 
tobacco (based on price and supply elasticities) to the value of statistical life (conservatively 
valued as 1 times per capita GDP) weighted by tobacco-related mortality and the degree to which 
health smoking risks are known.  They conclude that if a typical smokers underestimates his or 
her own health costs by 3% to 23%, then the net benefits of consumption are zero. Similarly, the 
marginal costs of a 10% higher price due to taxation have net welfare gains as long as 3% of 
smokers or more underestimate their health risks of smoking.  
While acknowledging the importance of attempts to estimate welfare losses associated 
with tobacco addiction, our approach in this paper is simpler.  We use published estimates of the 
costs of mounting a comprehensive tobacco control program (analogous to the “combination 
prevention” approach to HIV transmission).  CDC has recommended expenditures of $1-4 per 
capita, but some US states have done well with less.  DCP2 estimates expenditures for India of 
about $80 million per year.  This figure includes costs of mobilizing public support, anti-
smoking advertising and promotion, support for cessation programs and tax administration costs.  
Higher tobacco taxes raise net revenue, so with this perspective, tobacco taxation is cost savings.  
However, our B:C analysis is based on social costs, and treats the implementation costs of 
comprehensive tobacco control program (of taxes and non-price interventions) like the 
implementation costs of other health programs.  
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In light of the range of published program cost we use $1 billion per year as a reasonable 
estimate of the cost of comprehensive programs in the low- and middle-income countries.  Our 
specific estimates of mortality reduction are based on the effect of a 33% price increase (about a 
50% increase in tax) on demand. 
 
 
7.    OPPORTUNITIES FOR DISEASE CONTROL 
 
 
The preceding three sections identified a range of attractive options for disease control 
based, for the most part, on the 315 interventions that DCP2 reviewed (Jamison, et. al. 2006).  
Laxminarayan, et. al. (2006) summarizes the main findings on cost-effectiveness, which form the 
basis for the cost-benefit analyses reported here.  Appendix Table 1 provides highlights of those 
findings for South Asia and Sub-Saharan Africa.  One thing that is clear in the summarization of 
the cost-effectiveness information is that there is a broad range of reasonable estimates for most 
interventions.  This results partly from (often highly) incomplete information and uncertainty.  It 
results also, and even more importantly, from the responsiveness of the cost-effectiveness 
function to variations in prices, in the scale of the intervention (and of its substitutes and 
complements), and in the epidemiological environment. 
Given these often broad ranges in CE ratios, and hence in CB ratios, it makes little sense 
to conclude with precise estimates or with attempts to quantify uncertainty.  Rather we have 
identified seven major opportunities for investment in interventions that address a large disease 
burden highly cost effectively.  Even valuing DALYs at a conservative $1,000 and, again 
conservatively, reducing by 50% the DALY associated with an under-5 death (this affects the 
malaria and immunization numbers) the benefit-to-cost ratios associated with investing in these 
opportunities is enormously high.  (Appendix B provides a brief assessment of the sensitivity of 
our findings to key assumptions.)  Overall this suggests that the conclusions we summarize in 
Table 6 are conservative, principally because of the low value of $1000 attached to DALYs for 
the computations reported in that table. 
This concluding section provides a summarizing table not ranked on these 7 
interventions.  First on the list in Table 6 is case finding and treatment of tuberculosis (Dye and 
Floyd, 2006).  The 7
th item, strengthening and expanding surgical capacity at the district hospital   
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a   Level of capacity required, extent of financial risk protection provided and relevance for development assistance are 
judged by the authors to be high (H), medium (M) or low (L). 
b  In the formulation of DALYs the benefits of averting a death in a given year all accrue in that year and are calculated as 
the present value (at a 3% discount rate) of the future stream of life years that would have occurred if the death had been 
prevented.   
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level (Debas, et. al. 2006) is an essentially systems-oriented intervention.  Although the list of 
conditions that district hospital surgeons address is long, the most important in terms of benefits 
are dealing with difficult childbirths and with injury. 
Table 6 includes information on cost-benefit ratio and on total costs and benefits as well 
as judgments on other key parameters.  Every opportunity in the table has not only a very high 
estimated B:C ratio but, also, addresses major disease burden.  The interventions that would 
address the most DALYs are TB treatment and district hospital surgery.  Each would provide 
relatively a high degree of financial protection to populations. 
Experience with implementation of heart attack treatment and, to a lesser extent, tobacco 
taxation and surgery, is much more limited in low-income countries than is experience with the 
other four interventions on the list.  There is a strong case for early, large-scale implementation 
trials in each of these three areas, and correspondingly strong arguments for international 
development assistance to finance these trials and learn from their results. 
With the exception of surgery in the district hospital, the opportunities identified do not 
explicitly address the strengthening of health system capacity.  It will be important to ensure that 
implementation includes related investments in manpower and institutions, with ‘related’ broadly 
defined.  One might consider there to be two broad approaches to strengthening health systems.  
One involves relatively non-specific investments in capacity and reforms of process.  The second 
involves creating health system capacity to achieve specific measurable outcomes with high 
quality, a so-called ‘diagonal’ approach (Sepulveda, 2006).  In the second model capacity 
strengthening spreads out from high-performing initial nodes.  The approach that this paper 
implicitly advocates is very much in the spirit of the latter. 
From national perspectives the interventions on HIV/AIDS (combination prevention), on 
TB, on immunization and on malaria prevention appear as very high priorities.  Given that, for 
whatever reason, these interventions remain underfunded, there is a reasonable argument that 
development assistance funds should address these needs and to an important extent they do 
(through the very substantial resources of GAVI and the Global Fund Against AIDS, 
Tuberculosis and Malaria).  But most of these are familiar interventions with only modest 
international externalities. There is a reasonable argument that development assistance should 
deal with R&D, with reducing the risks of adopting new methods and with crossborder 
externalities.  By these criteria development assistance is doing less well in all but ignoring heart  
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disease and surgical capacity.  There is an initiative now being considered seriously by the 
international community to facilitate less expensive treatment with effective malaria drugs while 
preventing the development of resistance to the key drug artemisinin.  The Affordable Medicines 
Facility-malaria (AMFm) would operate by changing the prices countries face for drugs rather 
than supporting their purchase, and its support is a key priority.    
All the interventions in the table have advantages and disadvantages relative to each 
other, and different individuals might well order them differently.  The overwhelming general 
conclusion, however, is that even if all costs were increased by a factor of, say, 3 (Appendix 
Table B1, row 3), there is a substantial and very specific list of major and highly attractive 

































Appendix A: Intervention Cost-Effectiveness in South Asia and Sub-Saharan Africa 
 
 
DCP2 attempted to provide separate estimates of intervention cost-effectiveness for each of the 
World Bank’s six regional groupings of low- and middle-income countries.  The emphasis for 
the Copenhagen Consensus, and for this paper, is on low-income countries, which are 
concentrated in South Asia and Sub-Saharan Africa.  Appendix Table 1 summarizes key DCP2 





































Appendix Table A1:   Neglected Low-Cost Opportunities and High Cost Interventions in 
South Asia and Sub-Saharan Africa 
                                                                                                                                   (Continues on next page)  
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Source:  This table is based on chapters in Disease Control Priorities in Developing Countries, 
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Appendix B: Sensitivity Analysis 
 
The analysis upon which we based the conclusions reported in Table 6 was based on the 
following assumptions: 
   
1.  The DALY that was used was based on a 3% discount rate and no age weighting.  These 
are the assumptions used in the most recent presentation of methods, data sources and 
results on the global burden of disease (Lopez et al, 2006a, 2006b).  Earlier tabulations of 
disease burden used age-weighted DALYs, which give broadly similar results except that 
somewhat more weight is given to conditions of middle age (TB, maternal deaths, 
trauma, psychiatric illness). 
 
2.  Chapter 6 (Jamison, et al, 2006) of Lopez (2006a) points to the mathematical 
impossibility, under plausible assumptions, of having the standard formulation of a 
DALY give a loss from a death at age 25 that would differ by more than 20% or so from 
the loss from a death at age 1 day. An alternative version of the DALY is proposed there 
[DALY (3,0, .54)] and used in this chapter.  The effect is to reduce the DALY of a death 
under age 5 by about 50% without changing the DALY from deaths at older ages. 
 
3.  In an attempt to include relevant health systems costs and to take a long-run view, cost 
estimates in this chapter are based on long-run average costs (at least in principle, as there 
is some variation in actual costing methods). 
 
4.  The chapter assumes zero deadweight loss from taxation. 
 
5.   The chapter assumes the value of a DALY to be $1000. 
 
Appendix Table B1 reports assessments of the robustness of our conclusions with respect 
to changes in these assumptions.  On the most optimistic alternative assumption of Appendix 
Table B1, the B:C for immunization and for malaria would increase by a factor of 10; for the 
other interventions the factor is 5.  Taking the least optimistic assumptions, the B:C of all 
interventions would decline by a factor of 10.  
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Appendix Table B1: Sensitivity Analysis 
 
 





1. Change the discount rate from 3% to 6% per 
year, i.e. change to DALYs (6,0,.54). 
 
 
The number of DALYs averted from each of 




2. Change from DALYs (3,0,.54) to DALYs 
(3,0). 
 
The number of DALYs averted from 
immunization and from malaria control will 




3. Since ex ante costs are typically 
underestimated, often substantially, multiply 
all costs by 3. 
 
 
B:C will decline to 1/3 of its otherwise 
estimated value for all interventions. 
 
4. The deadweight loss from taxation is 
increased from 0 to 50% of the revenue raised 
(Ballard, Shoven and Whalley, 1985, provide 
estimates in this range). 
 
 
B:C value will decline by 1/3. 
 
5. The value of a DALY averted is $5000 
rather than $1000. 
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